지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.9
- 수록면
- 173 - 179 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: Triple negative breast cancer (TNBC) has had poor prognosis compared with the luminal subtype. And there has been no benefit from doxorubicin. However, the addition of paclitaxel is known to improve both disease-free survival (DFS) and overall survival (OS). The aim of our study was to assess the effect of the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide in TNBC.
Methods: We randomly selected 87 women from 104 women with TNBC who had been randomly assigned to receive doxorubicin (60 ㎎ per square meter of body-surface area) plus cyclophosphamide (600 ㎎ per square meter) for four cycles, followed by four cycles of paclitaxel (175 ㎎ per square meter) or two more cycles of doxorubicin plus cyclophosphamide. Due to predictions of clinical outcomes in women who receive adjuvant paclitaxel based chemotherapy, immunohistochemical analyses of these tissue specimens for CK5/6 were used.
Results: Among patients with TNBC, 24 patients (27.6%) were classified as CK5/6-positive triple negative type. Twelve patients were classified as paclitaxel chemotherapy group and 75 patients were classified as no paclitaxel group. No interaction was observed between DFS or OS and paclitaxel regimens. CK5/6 was, however, not associated with a significant benefit from paclitaxel in our study.
Conclusion: In our study, the addition of paclitaxel after adjuvant treatment with doxorubicin (＜60 ㎎ per square meter) is not associated with DFS or OS in TNBC.
Methods: We randomly selected 87 women from 104 women with TNBC who had been randomly assigned to receive doxorubicin (60 ㎎ per square meter of body-surface area) plus cyclophosphamide (600 ㎎ per square meter) for four cycles, followed by four cycles of paclitaxel (175 ㎎ per square meter) or two more cycles of doxorubicin plus cyclophosphamide. Due to predictions of clinical outcomes in women who receive adjuvant paclitaxel based chemotherapy, immunohistochemical analyses of these tissue specimens for CK5/6 were used.
Results: Among patients with TNBC, 24 patients (27.6%) were classified as CK5/6-positive triple negative type. Twelve patients were classified as paclitaxel chemotherapy group and 75 patients were classified as no paclitaxel group. No interaction was observed between DFS or OS and paclitaxel regimens. CK5/6 was, however, not associated with a significant benefit from paclitaxel in our study.
Conclusion: In our study, the addition of paclitaxel after adjuvant treatment with doxorubicin (＜60 ㎎ per square meter) is not associated with DFS or OS in TNBC.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
참고문헌 (23)
참고문헌 신청
1. [학술지(정기간행물)] - Goldhirsch A / 2007 / Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 / Ann Oncol 18 : 1133 ~ 1144
2. [학술지(정기간행물)] - Kim MJ / 2006 / Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu- overexpressing phenotypes / Hum Pathol 37 : 1217 ~ 1226
3. [학술지(정기간행물)] - Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) / 2005 / Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials / Lancet 365 : 1687 ~ 1717
4. [학술지(정기간행물)] - Perou CM / 2000 / Molecular portraits of human breast tumours / Nature 406 : 747 ~ 752
5. [학술지(정기간행물)] - Smith I / 2006 / Medical treatment of early breast cancer. I: adjuvant treatment / BMJ 332 : 34 ~ 37
2. [학술지(정기간행물)] - Kim MJ / 2006 / Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu- overexpressing phenotypes / Hum Pathol 37 : 1217 ~ 1226
3. [학술지(정기간행물)] - Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) / 2005 / Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials / Lancet 365 : 1687 ~ 1717
4. [학술지(정기간행물)] - Perou CM / 2000 / Molecular portraits of human breast tumours / Nature 406 : 747 ~ 752
5. [학술지(정기간행물)] - Smith I / 2006 / Medical treatment of early breast cancer. I: adjuvant treatment / BMJ 332 : 34 ~ 37
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Stalility of Paclitaxel with Cephalosporines in 0.8 Sodium Chloride Injection and 5 Dextrose Injection During Simulated Y-Site Administration
한국임상약학회지
2003 .01
-
Clinical Comparison between Paclitaxel Liposome (Lipusu) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Enhanced Paclitaxel Bioavailability after Oral Administration of Paclitaxel Coadministered with Quercetin in Rats.
대한약학회 학술대회
2002 .01
-
Effect of Ethyl Pyruvate on Paclitaxel-Induced Neuropathic Pain in Rats
The Korean Journal of Pain
2013 .01
-
흰쥐의 위점막에 Paclitaxel (Taxol)과 방사선조사의 효과
Radiation oncology journal : ROJ
1999 .01
-
Mass Production of Paclitaxel by Plant Cell Culture
대한약학회 학술대회
2000 .01
-
횐쥐의 대장점막에 Paclitaxel(Taxol)과 방사선조사의 효과
Radiation oncology journal : ROJ
1999 .01
-
Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2014 .01
-
흰쥐의 소장점막에 Paclitaxel(Taxol)과 방사선조사의 효과
Radiation oncology journal : ROJ
1996 .01
-
Paclitaxel-Platinum 제제를 기본으로 한 항암화학요법 후 재발한 난소암 환자에서 Paclitaxel-Carboplatin 복합항암화학요법의 효용성
Obstetrics & Gynecology Science
2004 .01
-
Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
Cancer Research and Treatment
2004 .01
-
Paclitaxel Suppress Dedifferentiation via Mitogen-activated Protein Kinase Pathway in Rabbit Articular Chondrocyte
대한의생명과학회지
2009 .03
-
프라본과 파크리탁셀과의 약물상호작용
약학회지
2003 .01
-
전이성 또는 재발성 위암에 대한 저용량 paclitaxel과 cisplatin 복합 화학요법
대한내과학회지
2005 .01
-
Identification of P-Glycoprotein and Transport Mechanism of Paclitaxel in Syncytiotrophoblast Cells
Biomolecules & Therapeutics(구 응용약물학회지)
2014 .01
-
Paclitaxel Stimulates Cyclooxygenase-2 Expression via MAP Kinase Pathway in Rabbit Articular Chondrocytes
대한의생명과학회지
2009 .06
-
Feasibility of using DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
한국실험동물학회 학술발표대회 논문집
2020 .02
-
진행성 비소세포폐암에 대한 2차 화학요법으로 paclitaxel과 cisplatin의 제 2상 임상연구
영남의대학술지
2004 .01
-
Efficacy of Combination Chemotherapy with Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell LungCancer
Cancer Research and Treatment
2002 .01
-
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer
Cancer Research and Treatment
2003 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0